


WHAT IS CLAIMED IS:

1. A compound of the formula:



I

- 5 or a pharmaceutically acceptable salt thereof,
wherein

R¹ is hydrogen or alkyl;

R² is alkyl, haloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl,
cycloalkylalkyl, heteroalkylsubstituted cycloalkyl, heterosubstituted
10 cycloalkyl, heteroalkyl, cyanoalkyl, heterocyclyl, heterocyclylalkyl, or -Y¹-
C(O)-Y²-R¹¹ (where Y¹ and Y² are independently either absent or an
alkylene group and R¹¹ is hydrogen, alkyl, haloalkyl, hydroxy, alkoxy,
amino, monoalkylamino or dialkylamino);


R³ is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heterosubstituted cycloalkyl,
15 heterocyclyl, aryl, aralkyl, haloalkyl, heteroalkyl, cyanoalkyl, -alkylene-
C(=O)-R⁴ (where R⁴ is hydrogen, alkyl, hydroxy, alkoxy, amino,
monoalkylamino or dialkylamino), or acyl;

Ar¹ is aryl;

X¹ is O, NR⁵ or S, where R⁵ is hydrogen or alkyl; and

20 X² is a bond, O, NR⁶, S or CH₂, where R⁶ is hydrogen or alkyl.

2. The compound according to Claim 1 of the formula:



3. The compound according to Claim 2, wherein X¹ is O.

4. The compound according to Claim 3, wherein R¹ is hydrogen.

5. The compound according to Claim 4, wherein R^3 is hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl or heteroalkyl.

6. The compound according to Claim 5, wherein R^3 is alkyl, heterocyclyl, heterosubstituted cycloalkyl or heteroalkyl.

5 7. The compound according to Claim 4, wherein R^2 is heteroalkyl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl, heteroaryl or aryl.

8. The compound according to Claim 7, wherein R^2 is optionally substituted phenyl.

9. The compound according to Claim 8, wherein R^2 is heterocyclylphenyl, alkylthiophenyl, alkylsulfinylphenyl, alkylsulfonylphenyl, phenyl, halophenyl, hydroxyphenyl, acylphenyl, cyanophenyl, alkoxy carbonylphenyl, carboxamidophenyl, N-alkylcarboxamidophenyl, N,N-dialkylcarboxamidophenyl, alkylsulfonyloxyphenyl, carbamoylphenyl, N-alkylcarbamoylphenyl or N,N-dialkylcarbamoylphenyl

10. The compound according to Claim 9, wherein R^3 is alkyl, heterocyclyl, heterosubstituted cycloalkyl or heteroalkyl.

11. The compound according to Claim 7, wherein Ar^1 is 2-halophenyl, 4-halophenyl, 2,4-dihalophenyl, 2,6-dihalophenyl, 2-alkylphenyl, 1-alkoxyphenyl, 2-alkoxyphenyl, 4-alkoxyphenyl, 3,5-dialkoxyphenyl, 2-halo-5-alkoxyphenyl or 2-dialkylamino-6-fluorophenyl.

12. The compound according to Claim 2, wherein R^1 is hydrogen.

13. The compound according to Claim 12, wherein R^2 is heteroalkyl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl, heteroaryl or aryl.

14. The compound according to Claim 13, wherein R^3 is hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl or heteroalkyl.

15. The compound according to Claim 14, wherein Ar^1 is 2-halophenyl, 4-halophenyl, 2,4-dihalophenyl, 2,6-dihalophenyl, 2-alkylphenyl, 1-alkoxyphenyl, 2-alkoxyphenyl, 4-alkoxyphenyl, 3,5-dialkoxyphenyl, 2-halo-5-alkoxyphenyl or 2-dialkylamino-6-fluorophenyl.

16. The compound according to Claim 1, wherein X^2 is a bond or CH_2 .

17. The compound according to Claim 16, wherein R^3 is hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl or heteroalkyl.

18. The compound according to Claim 17, wherein R^1 is hydrogen.

5 19. The compound according to Claim 18, wherein R^2 is heteroalkyl, heterocyclyl, or heterosubstituted cycloalkyl.

20. The compound according to Claim 19, wherein X^1 is O.

21. A composition comprising:

- 10 (a) a compound of Claim 1; and
(b) a pharmaceutically acceptable excipient.

22. A method for treating a p38 MAP kinase mediated disorder comprising administering to a patient in need of such treatment, an effective amount of a compound of Claim 1.


15 23. The method of Claim 22, wherein the p38 mediated disorder is arthritis, Crohn's disease, inflammatory bowel disease, adult respiratory distress syndrome, or chronic obstructive pulmonary disease.

24. The method of Claim 22, wherein the p38 mediated disorder is Alzheimer's disease.


20 25. A method for treating an FGFR kinase mediated disorder comprising administering to a patient in need of such treatment, an effective amount of a compound of Claim 1.

26. The method of Claim 25 wherein the FGFR kinase mediated disorder is atherosclerosis, restenosis or cancer.

27. A method for producing a compound of the formula:



said method comprising the steps of contacting a compound of the formula:



with an amine compound of the formula R^1R^2NH to produce a compound of Formula.
wherein

R^1 is hydrogen or alkyl;

R^2 is alkyl, haloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloalkylalkyl, heteroalkylsubstituted cycloalkyl, heterosubstituted cycloalkyl, heteroalkyl, cyanoalkyl, heterocyclyl, heterocyclylalkyl or $-Y^1-C(O)-Y^2-R^{11}$ (where Y^1 and Y^2 are independently either absent or an alkylene group and R^{11} is hydrogen, alkyl, haloalkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino);

R^3 is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, aryl, aralkyl, haloalkyl, heteroalkyl, cyanoalkyl, $-alkylene-C(=O)-R^4$ (where R^4 is hydrogen, alkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino) or acyl;

Ar^1 is aryl;

X^1 is O, NR^5 or S, where R^5 is hydrogen or alkyl;

X^2 is a bond, O, NR^6 , S or CH_2 , where R^6 is hydrogen or alkyl;

n is an integer from 0 to 2; and

R^7 is an alkyl group.

28. The method of Claim 27 wherein:

R¹ is hydrogen;

R² is heteroalkyl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl, heteroaryl or aryl;

R³ is hydrogen, alkyl, aryl, cycloalkyl, heterocyclyl, heterosubstituted cycloalkyl or heteroalkyl;


Ar¹ is aryl;

X¹ is O;

X² is a bond; and

n is 1 or 2.

29. A compound of the Formula:



wherein

n is 0, 1, or 2;

R³ is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, aryl, aralkyl, haloalkyl, heteroalkyl, cyanoalkyl, -alkylene-C(=O)-R⁴ (where R⁴ is hydrogen, alkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino) or acyl;

R⁷ is alkyl;

Ar¹ is aryl;

X¹ is O, NR⁵ or S, where R⁵ is hydrogen or alkyl; and

X² is a bond, O, NR⁶, O or CH₂, where R⁶ is hydrogen or alkyl.

30. The compound of claim 10, wherein R³ is methyl.

31. The compound of claim 30, wherein R² is 4-(morpholin-4-yl)phenyl.

32. The compound of claim 31, wherein Ar¹ is 2-bromophenyl.
33. The compound of claim 31, wherein Ar¹ is 2,6-dichlorophenyl.
- 5 34. The compound of claim 30, wherein R² is 3-methylsulfinylphenyl.
35. The compound of claim 34, wherein Ar¹ is 2-bromophenyl.

* * * * *

10